Heyu Medical's ValveClamp® Mitral Valve Clip System Listed in Shanghai's 'New & Superior Biopharmaceutical Products Catalog'

Oct 25, 2024 09:00 CST Updated 09:00

Hanyu Medical

Structural Heart Disease Interventional Devices and Electrophysiology Product R&D, Manufacturer

Recently,ShanghaiHanyu Medical TechnologyCo., Ltd.（Hereinafter referred to as: Hanyu Medical）The“Mitral Valve Clip System”Successfully made it to the list of {Shanghai's Biomedical "New and Excellent Medical Devices"Product Catalog》.The directory was compiled by the Editorial Board (ShanghaiScience and TechnologyMember、Shanghai Municipal Health Commission, Shanghai Medical Security Bureau, Shanghai Drug Administration, and Shanghai Shenkang Hospital Development Center) have approved the initiative to promote the innovative development of the biopharmaceutical industry.

Hanyu Medical Always Adheres to Patient Needs as the Guiding Principle; This Successful Achievement Injects Strong Momentum into the Company’s Development. The Significant Innovation and High Safety of the Mitral Valve Clip System Will Undoubtedly Bring Benefits to More Patients with Mitral Regurgitation."The Gospel of the Heart."

[Product Introduction]

ValveClamp® Mitral Valve Clip System consists of a mitral valve clip, delivery system, and transvalvular device.This product is the world's first transapical mitral valve clip device.Compared with traditional surgical treatment options, interventional therapy has the advantages of high safety and small wounds, making it suitable for critically ill patients, those with weak constitutions, multiple comorbidities, and high surgical risks, providing clinical practice with a new therapeutic choice.Compared with previous devices such as MitraClip and Pascal, ValveClamp adopts the transapical approach, with a shorter distance from the device entry incision to the mitral valve, making the delivery system easier to align coaxially with the native valve. The position and angle of the device can be directly controlled, providing more sensitive and precise mechanical transmission. The operation is convenient and can be completed under ultrasound assistance in a regular surgical operating room, while avoiding X-ray exposure for both patients and doctors.

[Company Introduction]

Shanghai Hanyu Medical Technology Co., Ltd. (Hanyu Medical) was established at the end of 2016 and is located in Minhang District, Shanghai.
With the mission of "Defending Life, Benefiting the World," the company mainly engages in the research, development, production, and commercialization of interventional devices for structural heart diseases. It owns subsidiaries such as Hanyu Medical, Singapore Hanyu, and Guangdong Hanyu.
In the field of structural heart disease interventional devices, the innovative medical device "ValveClamp® Mitral Valve Clip System" developed by Shanghai Hanyu Medical Technology Co., Ltd. was officially approved by the National Medical Products Administration in early September 2023, becoming the first domestically produced mitral regurgitation interventional device approved for marketing in China. The product has also been approved for marketing in Indonesia in March 2024.
The company has laid out a precise and diversified pipeline of products under research in this field: the novel atrial septal defect occluder ReAces (Chinese name: Rui Ao) has completed clinical enrollment and is currently in follow-up; the percutaneous mitral valve clip and delivery system ValveClasp entered the National Innovative Medical Device Special Review Process in 2023 and is currently undergoing clinical enrollment. The company's products have been clinically applied in more than 60 hospitals in China and are commercially sold in over 20 countries worldwide. With the goal of comprehensively addressing unmet clinical needs in the field of structural heart disease in China and globally, the company provides patients with high-quality, cost-effective integrated cardiac disease solutions to improve survival rates, life expectancy, and quality of life.